CClinicalTrials.gg
CompletedNCT05480774Updated Jan 31, 2023

Effect of Red Ginseng Extract on Changes in Indicators of Immune Function in Vietnamese Healthy Volunteers

A Phase 1 interventional study of KRG hard capsule and Placebo hard capsule in Healthy, sponsored by Centre of Clinical Pharmacology, Hanoi Medical University. Completed at 1 site in Vietnam. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Centre of Clinical Pharmacology, Hanoi Medical University · Phase 1, Interventional, and Supportive care

Phase
Phase 1
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

This is a placebo-controlled, randomized, double-blind, multiple dose study that evaluated the safety, tolerability, and changes in indicators of immune function of Korean Red Ginseng Extract in Vietnamese healthy subjects following oral administration of multiple dose of Korean Red Ginseng Extract as hard capsules or placebo to healthy adult men.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Centre of Clinical Pharmacology, Hanoi Medical University is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adult male or female aged 20 to 65 years, inclusive at the time of informed consent
  • Have not any abnormalities of vital signs (temperature, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and pulse rate), physical examinations, clinical laboratory tests (hematology, chemistry, and urinalysis).
  • Ability and willingness to provide written informed consent and to comply with the requirements of the protocol.
  • Peripheral white blood cells in the range of 3000 - 10,000/μL
  • Subjects with a history of being infected with COVID-19 within 12 months according to the diagnostic criteria of the Ministry of Health at the time of infection

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • For subjects of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception
  • Evidence of clinically significant acute or chronic hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psych, neurological, or neoplastic diseases (however, at the discretion of the principal investigator, subjects may also be considered)
  • Uncontrolled hypertension (SBP ≥160 mmHg and/or DBP ≥100 mmHg, measured following at least 10 mins of rest)
  • Uncontrolled diabetes (fasting glucose level above 126 mg/dL or diabetic patients who have initial treatment with antidiabetic drugs for ≤ 3 months)
  • Aspartate aminotransferase or alanine aminotransferase >=3.0 × upper limit of normal
  • Serum creatinine level > 2,4 mg/dL for male and > 1,8 mg/dL for female
  • Use of medications and dietary supplements that can affect immunity within 2 weeks before screening
  • Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion
  • History of sensitivity or allergy to investigational product-related foods
  • Plan to participate in other research while participating in this research
  • Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study.
  • Failure of follow instructions for discontinuing immune-affecting dietary supplements during the wash-out period prior to trial participation
05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Active comparator
    KRG hard capsules

    Each KRG hard capsule contains 500 mg of red ginseng extract. Dosage of KRG hard capsule: oral administration of 1 capsule twice daily for 12 weeks.

    Drug: KRG hard capsule

  • Placebo comparator
    Placebo hard capsules

    The composition of the Placebo hard capsule contains red ginseng flavor. Dosage of Placebo hard capsule: oral administration of 1 capsule twice daily for 12 weeks.

    Drug: Placebo hard capsule

Interventions

  • DrugKRG hard capsule

    Each subject was given orally 2 KRG hard capsules/day for 12 weeks

  • DrugPlacebo hard capsule

    Each subject was given orally 2 placebo hard capsules/day for 12 weeks

06

What researchers measure

Primary outcomes

  1. Adverse events associated with the administration of KRG

    Frequency and characteristics of adverse events associated with the administration of KRG

    Time frame: 12 weeks

Secondary outcomes

  1. Natural killer (NK) cell count

    Change in NK cell count after 12 weeks compared to baseline

    Time frame: 12 weeks

  2. White blood cell count

    Change in white blood cell count after 12 weeks compared to baseline

    Time frame: 12 weeks

  3. Interferon (IFN)-α, β, γ levels

    Changes in IFN-α, β, γ levels after 12 weeks compared to baseline

    Time frame: 12 weeks

  4. Tumor necrosis factor (TNF)-α, β, γ levels

    Changes in TNF-α, β, γ levels after 12 weeks compared to baseline

    Time frame: 12 weeks

  5. Interleukin (IL)-1, 4, 6 levels

    Changes in IL-1, 4, 6 levels after 12 weeks compared to baseline

    Time frame: 12 weeks

07

Study locations

1 site
  • Centre of Clinical Pharmacology
    Hanoi, Vietnam
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05480774
Lead sponsor
Centre of Clinical Pharmacology, Hanoi Medical University
Collaborators
Kyunghee University, HK inno.N Corporation
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Aug 6, 2022
Primary completion
Dec 3, 2022
Completion
Dec 31, 2022
Last update
Jan 31, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion